Biostem Technologies (BSEM) Company presentation summary

Mission and vision

• Focused on delivering advanced wound healing technologies to improve patient outcomes.

• Committed to innovation in regenerative medicine, particularly perinatal tissue allografts.

Market opportunity and industry need

• Addresses a $23B US soft tissue allograft market across orthopedics, wound care, urology, spine, and women’s health.

• Regenerative medicine aims to reduce $30B+ in annual healthcare costs from infections and complications.

• Significant patient impact with ~155,000 lower limb amputations and ~800,000 diabetic foot ulcer hospitalizations annually.

Product portfolio and technology

• Offers a comprehensive suite of perinatal tissue allografts, including Clarix, Neox, and Vendaje brands.

• Proprietary platforms: BioREtain®, CryoTek®, and SteriTek® preserve natural tissue properties for optimal healing.

• 58 issued US patents and 68 pending, with 90+ clinical publications supporting product efficacy.